Input to public consultation on the Swiss Ordinance on Health Insurance

    5 Oct, 2016

    The RDAF provided input to the public consultation launched by the Federal Office of Public Health (FOPH) on the Swiss Ordinance on Health Insurance (KVV/OAMal). The RDAF’s input included action oriented suggestions for improving patient access to treatment and focused on aspects that are most important for the area of rare diseases such as the reimbursement process applying to individual cases (the so-called article 71 KVV reimbursement process).

    Continue reading

    Boehringer Ingelheim joins the Rare Disease Action Forum

    We are delighted to announce Boehringer Ingelheim as new member of the Rare Disease Action Forum. Boehringer Ingelheim’s membership fortifies RDAF's multi-stakeholder base, alongside other members from industry, patient organizations, healthcare professionals, and...